Overview

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Status:
Completed
Trial end date:
2019-04-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept